Viridian Therapeutics Inc (VRDN)
Healthcare
Biotechnology
18.90 $
-4.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Viridian Therapeutics Inc (VRDN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 88.5% of the shares are freely tradable; institutional investors hold 109.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
109.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
88.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
14.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
110Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.92 | 15,379,377 | +6.9 | 03/31/2026 |
| BlackRock Inc | 7.60 | 7,831,475 | +21.8 | 03/31/2026 |
| Bellevue Group AG | 6.53 | 6,726,144 | +54.3 | 03/31/2026 |
| Vanguard Group Inc | 5.44 | 5,612,144 | +29.6 | 12/31/2025 |
| State Street Corp | 4.53 | 4,672,885 | +34.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.04 | 4,167,201 | +0.0 | 03/31/2026 |
| Fairmount Funds Management LLC | 3.80 | 3,914,458 | +0.0 | 03/31/2026 |
| VR Adviser, LLC | 3.77 | 3,882,709 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 3.11 | 3,206,035 | -6.8 | 03/31/2026 |
| Paradigm Biocapital Advisors LP | 3.06 | 3,148,893 | +118.2 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.